"Other health problems don't go away during a pandemic. An LLYC Task Force is ready to offer solutions to raise awareness of research and development advances toward new therapies that tackle diseases and save lives."
Since the beginning of the health and economic crisis caused by the COVID-19 outbreak, a number of pharmaceutical companies and medical teams have been racing to find new therapies, develop diagnostic tests and create a vaccine, all with the goal of treating and curing the disease.
This social and scientific phenomenon sits somewhere between a health and economic priority. It has given rise to endless questions about how the virus behaves, the chances of finding new treatments and vaccines in record time, citizen access to these new options and even a new reality, which would mean changing how we live, interact with others and do business. For example, telemedicine is being heavily promoted, and it will likely play a meaningful role in the near future.
In a situation such as this, it is essential to create a positive business environment by supporting regulatory improvements capable of accelerating the medicine approval process, promoting investments in innovation and protecting intellectual property. Throughout this process, patients must remain at the heart of all decisions. The pandemic should not impact access to innovative medicines for other pathologies.
That’s why LLYC offers solutions to help companies build trust through clear communications and tackle the post-COVID challenges, all while looking toward the future.
This social and scientific phenomenon sits somewhere between a health and economic priority. It has given rise to endless questions about how the virus behaves, the chances of finding new treatments and vaccines in record time, citizen access to these new options and even a new reality, which would mean changing how we live, interact with others and do business. For example, telemedicine is being heavily promoted, and it will likely play a meaningful role in the near future.
In a situation such as this, it is essential to create a positive business environment by supporting regulatory improvements capable of accelerating the medicine approval process, promoting investments in innovation and protecting intellectual property. Throughout this process, patients must remain at the heart of all decisions. The pandemic should not impact access to innovative medicines for other pathologies.
That’s why LLYC offers solutions to help companies build trust through clear communications and tackle the post-COVID challenges, all while looking toward the future.
Challenges.
WHICH NEW APPROACHES IN RESEARCH OR DOING BUSINESS WILL BE REQUIRED BY THE PHARMACEUTICAL INDUSTRY?
The situation caused by the pandemic represents an unprecedented opportunity to demonstrate the value of research and development on new therapies for tackling situations that affect health and for saving lives.
HOW TO MAKE PUBLIC-PRIVATE PARTNERSHIPS MORE VIABLE?
Collaboration on anticipating long-term health risks and problems should be at the center of any approach. From financing and cooperation initiatives to regulatory improvements capable of producing faster and more effective solutions.
IS IT TIME TO IMPLEMENT NEW TECHNOLOGIES?
Emerging technologies and digital solutions are proving critical in changing the future of healthcare. Their introduction requires a review of public policies on access to markets, intellectual protection and regulatory processes.
ARTICLES
Contact an LLYC expert.
Cases
Novartis
Bertelsmann and Sanitas
